Asset Details
Do you wish to reserve the book?
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Do you wish to request the book?
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
2019
Overview
Background
In this era of precision medicine, the DNA damage response (DDR) pathway has been shown to be a viable target of intervention in metastatic castration-resistant prostate cancer (CRPC) as approximately one-third of CRPC patients harbor DDR pathway mutations. To determine whether DDR pathway is a potential therapeutic target in localized disease, we analyzed The Cancer Genome Atlas (TCGA) in the present study.
Methods
TCGA is a publically available cancer genome database that is sponsored by the United States National Cancer Institute. Total of 455 cases were available in the database at the time of this analysis.
Results
DDR pathway gene mutations or copy number alterations were present in 136 (29.9%) of the 455 cases. On a univariate analysis, DDR pathway status did not correlate with serum prostate specific antigen, tumor stage or grade. However, among patients with high-risk features post-operatively (pathologic stage ≥ T3, Gleason score ≥ 8, or PSA > 20 ng/ml), DDR pathway alteration was associated with a lower overall survival (
p
= 0.0291).
Conclusions
Collectively these results suggest that DDR pathway alterations may also be significant in localized prostate cancer and agents such as PARP inhibitors should be considered in patients with a high-risk disease.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Adult
/ Aged
/ Antigens
/ Cellular signal transduction
/ Defects
/ DNA
/ Genes
/ Genomes
/ Genomics
/ Humans
/ Male
/ Medicine
/ Mutation
/ Patients
/ Prostatic Neoplasms - epidemiology
/ Prostatic Neoplasms - genetics
/ Prostatic Neoplasms - therapy
/ Tumors
/ Urology
